Latest Commercialization News

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

GreenTech Metals has fast-tracked its Phase 1 drilling at the Munni Munni PGE-Cu-Ni Project by deploying a second drill rig, aiming to upgrade and potentially expand its historic resource estimate to modern standards.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Temas Resources has confirmed its patented Regenerative Chloride Leach (RCL) technology can produce commercial-grade titanium dioxide with significant cost reductions, positioning the company for global licensing opportunities.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Sea Forest Limited has exceeded its breakeven target for its methane-reducing feed additive SeaFeed™, securing commitments for over 118,000 cattle and expanding commercial trials with major industry partners.

Hammer Metals reported steady progress across its Western Australian and Queensland gold and copper projects, highlighted by new drilling completions and a strategic acquisition at Mount Sefton. Assay results from key programs are eagerly awaited as the company strengthens its exploration pipeline.

Imricor Medical Systems has achieved a major milestone with FDA clearance for its NorthStar Mapping System, the first MRI-native 3D cardiac mapping platform approved in the US. This approval positions Imricor at the forefront of MRI-guided cardiac procedures in the world’s largest electrophysiology market.

Omega Oil and Gas has secured a 19.43% stake in Elixir Energy, positioning itself for a major drilling push in Queensland’s Taroom Trough during 2026. Backed by a strong balance sheet, Omega aims to unlock significant gas and oil resources across multiple projects.

Compumedics has landed a $4.2 million order for its advanced MEG system from Shandong Normal University, pushing total contracted MEG sales to around $30 million and extending revenue visibility into FY27.